Home Categories API Raltegravir (MK-0518)
A7134112

Raltegravir (MK-0518) , ≥97% , 518048-05-0

CAS NO.:518048-05-0

Empirical Formula: C20H21FN6O5

Molecular Weight: 444.42

MDL number: MFCD10698872

EINECS: 610-733-3

Pack Size Price Stock Quantity
5MG RMB520.00 In Stock
250mg RMB613.60 In Stock
10MG RMB892.00 In Stock
1g RMB1590.40 In Stock
50MG RMB2900.80 In Stock
others     Enquire
Update time: 2022-07-08

PRODUCT Properties

Melting point: 216 °C(Solv: isopropanol (67-63-0))
Density  1.46±0.1 g/cm3(Predicted)
storage temp.  -20°C Freezer
solubility  DMSO (Slightly), Methanol (Very Slightly)
pka 4.50±1.00(Predicted)
form  Solid
color  White to Light Beige
CAS DataBase Reference 518048-05-0(CAS DataBase Reference)

Description and Uses

Joining maraviroc as a unique approach to battling HIV-1, raltegravir, an inhibitor of HIV-1 integrase, represents the first in its class to be developed and launched as a combination treatment with other antiretroviral agents (NRTIs, NNRTIs, and PIs). HIV-1 integrase is essential for replication of the virus as a virally encoded enzyme that integrates the viral DNA into the genome of the host cell. Inhibition of HIV-1 integrase prevents the two-step process of endonucleolytic removal of the terminal dinucleotide from each 3′end of the viral DNA followed by the covalent integration of the viral DNA, at these modified 3′ends, into the host DNA, thereby representing a viable intervention in the viral life cycle. In vitro, raltegravir inhibited the strand transfer activity of HIV-1 integrase with an IC50 of 2–7nM with > 1,000-fold selectivity over other phosphoryltransferases. In addition, its in vitro IC95 for HIV-1 in 10% fetal bovine serum and 50% human serum was 19 and 33 nM, respectively. Raltegravir was well tolerated with no dose-related toxicities and a safety profile comparable to placebo. The most common clinical adverse events were diarrhea, nausea, vomiting, fatigue, headache, flushing, pruritus, and injection-site reactions.

Raltegravir (MK-0518) is a potent integrase (IN) inhibitor for WT and S217Q PFV IN.

Safety

Symbol(GHS) 
GHS07
Signal word  Warning
Hazard statements  H315-H319
Precautionary statements  P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313
Hazardous Substances Data 518048-05-0(Hazardous Substances Data)

RELATED PRODUCTS